1 March
2024
4basebio
PLC
("4basebio", the "Company"
or the "Group")
4basebio awarded
tender to deliver research and GMP-grade synthetic DNA
in
CPI's tender process for supplying its RNA Centre of
Excellence
Cambridge, UK, 1 March
2024 - 4basebio PLC (AIM: 4BB), an innovation-driven
biotechnology company enabling and accelerating the development of
advanced therapy medicinal products (ATMPs) through its
high-performant synthetic DNA products and non-viral, thermostable
nucleic acid delivery platform, today announces, that it has been
successful in a tender process to supply research and GMP-grade
synthetic DNA for the development of RNA therapeutics and vaccines
in CPI's RNA Centre of Excellence.
The tender process was
focussed on the manufacture of plasmid and synthetic DNA templates,
and 4basebio is able to fulfil CPI's DNA requirements for the
development and scale-up of novel RNA therapeutics. 4basebio's
synthetic opDNA™ templates confer several advantages for the
production of mRNA, not limited to superior transcriptional yields
and no need for enzymatic linearisation, alongside reduced
turnaround time, safety, and cost
benefits.
Heikki Lanckriet, CEO and CSO of 4basebio,
commented: " We are delighted to
have met CPI's RNA Centre of Excellence criteria for the supply of
DNA templates. Our growing client base recognises the benefits of
opDNA™ in mRNA production for clinical application and it is
rewarding to see this potential recognised by CPI as well. We aim
to support and accelerate the development of RNA medicines for the
organisations that CPI is working
with."
Julie Anderson, Head of RNA Centre of Excellence
at CPI added: "It is important for
CPI to include access to the high-quality DNA templates produced by
4basebio to our clients for the development and manufacture of RNA
therapeutics. We are impressed by the capabilities of the
4basebio team and are looking forward to including their synthetic
templates in the development of our partners' RNA
medicines."
For further enquiries,
please contact:
4basebio
PLC
+44 (0)12 2396 7943
Heikki
Lanckriet
Nominated
Adviser
+44 (0)20 7213 0880
Cairn
Financial Advisers
LLP
Jo Tuner / Sandy
Jamieson
Broker
+44 (0)20 7220 0500
Cavendish
Geoff Nash/Richard
Chambers/Charlotte
Sutcliffe
Lionsgate Communications
(Media
Enquiries)
+44 (0)77 91892509
Jonathan
Charles
Notes
to Editors
About
4basebio
4basebio (AIM: 4BB)
is an innovation driven life biotechnology company focussed on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high performant synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company' objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA
starting materials suitable for use in AAV viral vector production
as well as mRNA vaccine and therapeutics
production.
About
CPI
Developing next-generation medicine manufacturing
innovations to deliver tomorrow's vaccines and therapeutics. We
offer world-leading facilities and expertise in small molecules,
biologics, oligonucleotides, and complex medicines to accelerate
drug development and scale-up. We host the largest pool of RNA
biomanufacturing experts in the UK and offer complementary drug
delivery systems like lipid
nanoparticles.
We're creating agile, efficient, and sustainable
supply chains by convening actors across the pharma industry
ecosystem in a pre-competitive space and boosting the adoption of
industry 4.0 advanced processes and
digitisation.
We're a pioneering social
enterprise that accelerates the development, scale-up and
commercialisation of smart AgriFoodTech, energy storage,
HealthTech, materials, and pharma innovations. Through our
incredible innovation experts and infrastructure, we look beyond
the obvious to transform healthcare and drive towards a sustainable
future.
As a trusted partner of
industry, academia, government, entrepreneurs, and the investment
community, we connect the dots within the innovation ecosystem to
make great ideas and inventions a reality. We believe by working
together we can build a better collective future, and as part of
the High Value Manufacturing Catapult, we facilitate access to
world-class organisations to deliver transformation across
industries and landscapes.
Creating lasting global
impact from the North of England
and Scotland, we invest in people
and disruptive technologies to invigorate economies, create
circular supply chains and make our world a better
place.
Forward-looking
statements
This announcement may
contain certain statements about the future outlook for 4basebio.
Although the directors believe their expectations are based
on reasonable assumptions, any statements about future outlook may
be influenced by factors that could cause actual outcomes and
results to be materially different.
